News
-
-
PRESS RELEASE
Galimedix Therapeutics initiates Phase 1 study with oral small molecule, GAL-101, an amyloid beta (Aβ) aggregation modulator
Galimedix Therapeutics initiates Phase 1 study with oral small molecule GAL-101, targeting neurodegenerative diseases. Study focuses on safety, tolerability, and pharmacokinetics for Alzheimer's, dry AMD, and glaucoma treatments -
-
-
PRESS RELEASE
HyProMag USA Commences Process to Appoint EPCM Provider for Rare Earth Magnet Recycling and Manufacturing Project
CoTec Holdings Corp. and Mkango Resources Ltd. announce initiation of 'Request for Proposal' process for HyProMag USA rare earth magnet recycling and manufacturing project in the United States, targeting revenue in Q1 2027 -
-
-
-
-